As concentrações plasmáticas da proteína FAM3D estão mais elevadas em portadores de diabetes mellitus de tipo 2 tratados com sulfoniluréia

• Ano de defesa: 2015
• Autor(a) principal: Neves, José Antônio Januário
• Orientador(a): Giannella Neto, Daniel
• Banca de defesa: Giannella Neto, Daniel , Giannella, Maria Lúcia Cardillo Corrêa , Camacho, Cléber Pinto
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Nove de Julho
• Programa de Pós-Graduação: Programa de Pós-Graduação em Medicina – Ciências da Saúde
• Departamento: Saúde
• País: Brasil
• Palavras-chave em Português: diabetes mellitus; FAM3D; expressão gênica
• Palavras-chave em Inglês: diabetes mellitus; FAM3D; gene expression
• Área do conhecimento CNPq: CIENCIAS DA SAUDE
• Link de acesso: http://bibliotecatede.uninove.br/handle/tede/3317

Among the new cytokine Family with Sequence Similarity 3 (FAM3), a subfamily of proteins similar to cytokines known as FAM3D was identified. FAM3D is predominantly expressed in the gastrointestinal tract of healthy individuals. Plasma concentrations of FAM3D range according to the nutritional status presenting a postprandial increase and a reduction in the later post-absorptive period. It might be speculated that FAM3D is an inhibitor of insulin secretion, as it has been observed a significant increase in patients with pancreatic adenocarcinoma associated with T2D. Our aim was to quantitatively determine the plasma concentration of FAM3D, in a group of patients with T2D and comparing with patients with pre-Type 2 Diabetes Mellitus (pT2D) and Control (CTRL) individuals paired according to gender, age and body mass index in order to better elucidate the action of FAM3D as well as its pathophysiological role in T2D. We selected 90 patients comprising 15 male and 14 females diagnosed with T2D; 12 male and 15 female diagnosed pT2D; and 7 male and 9 female CTRL. Seventeen patients were excluded according to the inclusion and exclusion criteria. In total, 73 patients were included. All were submitted to measurement of anthropometric and biochemical tests, including HOMA-IR calculation and the determination of plasma concentrations of FAM3D by ELISA. The Kruskal-Wallis tests were used in the comparison of study groups, and the regression coefficient  of Spearman was calculated on correlation between plasma concentrations of FAM3D and other anthropometric and biochemical variables. The level of statistical significance was set at p <0.05. Among the groups there were no significant difference in the concentration of FAM3D, and the median±Q for the CTRL group (24.92ng/mL ± 9.11); pT2D (14.65ng/mL ± 6.02) and T2D (19.87ng/mL ± 5.39). The group of DM2 patients on sulfonylurea (23.42ng/mL ± 6.1) had higher values compared to the group treated with other oral antidiabetic drugs (14.9 ng/mL ± 7.30), p <0.05. There was no correlation of FAM3D between groups. Patients with T2D on sulfonylurea presented a higher concentration of FAM3D when compared with T2D patients treated with other oral antidiabetic drugs.